NASDAQ:PHVS

Pharvaris B.v Stock Insider Trading

Healthcare > Biotechnology

Buy PHVS

*Your capital is at risk

$30.14

+1.16 (+4.00%)

At Close: Jun 03, 2026

Pharvaris B.V Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -20.58. In total, the insiders bought 1.02M and sold 236.29K PHVS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-20.58
● Buy	1.02M shares
● Sell	236.29K shares
61% Buy Activity Moderate Positive Correlation
Sell Signal Medium Confidence Apr 30, 2026 Analysis Breakdown: Supported by a negative Insider Power Score of -20.58. Partially supported by a positive historical correlation. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 03, 2027 Buy	Stock Option (Right to Buy)	Glassman Robert Director	Director	16 500 Value: $462.0K
Mar 03, 2027 Buy	Stock Option (Right to Buy)	Schikan Johannes Gerardus Christiaan Petrus Director	Director	16 500 Value: $462.0K
Mar 03, 2027 Buy	Stock Option (Right to Buy)	Bjork Elisabeth Director	Director	16 500 Value: $462.0K
May 22, 2026 Buy	Common Stock M-Exempt	Nijdam Anna Principal Accounting Officer	Officer	5 501 Value: $110.0K
May 22, 2026 Sell	Common Stock S-Sale	Nijdam Anna Principal Accounting Officer	Officer	5 501 Value: $169.1K
May 22, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Nijdam Anna Principal Accounting Officer	Officer	5 501 Value: $110.0K
May 21, 2026 Sell	Common Stock S-Sale	Monges Viviane Director	Director	9 667 Value: $292.9K
May 21, 2026 Buy	Common Stock M-Exempt	Nijdam Anna Principal Accounting Officer	Officer	1 829 Value: $36.6K
May 21, 2026 Sell	Common Stock S-Sale	Nijdam Anna Principal Accounting Officer	Officer	1 829 Value: $56.0K
May 21, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Nijdam Anna Principal Accounting Officer	Officer	1 829 Value: $36.6K
May 21, 2026 Sell	Common Stock S-Sale	Nassif David W. CFO / Clo	C-Suite Officer	10 000 Value: $303.1K
May 20, 2026 Buy	Common Stock M-Exempt	Bjork Elisabeth Director	Director	10 000 Value: $80.5K
May 20, 2026 Sell	Common Stock S-Sale	Bjork Elisabeth Director	Director	10 000 Value: $293.2K
May 20, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Bjork Elisabeth Director	Director	10 000 Value: $80.5K
May 18, 2026 Buy	Common Stock J-Other	Modig Berndt Insider	Other	0 Value: $0
May 18, 2026 Sell	Common Stock S-Sale	Modig Berndt Chief Executive Officer	CEO / President	2 292 Value: $67.0K
May 15, 2026 Buy	Common Stock M-Exempt	Glassman Robert Director	Director	5 333 Value: $119.0K
May 15, 2026 Sell	Common Stock S-Sale	Glassman Robert Director	Director	5 333 Value: $159.1K
May 15, 2026 Sell	Common Stock S-Sale	Glassman Robert Director	Director	4 667 Value: $139.2K
May 15, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Glassman Robert Director	Director	5 333 Value: $119.0K
May 15, 2026 Sell	Common Stock S-Sale	Abele Stefan Andreas Chief Technical Ops Officer	Officer	8 748 Value: $260.9K
May 15, 2026 Sell	Common Stock S-Sale	Souverijns Wim Chief Commercial Officer	Officer	10 000 Value: $299.2K
May 12, 2026 Sell	Common Stock F-InKind	Lu Peng Chief Medical Officer	Officer	117 Value: $4K
May 11, 2026 Sell	Common Stock F-InKind	Lu Peng Chief Medical Officer	Officer	109 Value: $3K
May 01, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Lu Peng Chief Medical Officer	Officer	14 023 Value: $36.3K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT PHARVARIS B.V.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical ...

Read Full Profile Here